Menu
1-702-720-6310 info@microcapspecualtors.com

Editas loses its lead in the biotech race to launch the first CRISPR/Cas9 human study – Endpoints News


Endpoints News

Editas loses its lead in the biotech race to launch the first CRISPR/Cas9 human study
Endpoints News
And in the process of slipping behind, the biotech lost its lead to CRISPR Therapeutics. In CRISPR’s Q1 update $CRSP a few days ago CEO Rodger Novak noted that his group plans to file its CTA — clinical trial authorization in Europe — in late 2017

and more »

Search